-
1
-
-
0027394923
-
A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group
-
Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PF, Briët E. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
-
(1993)
Blood
, vol.81
, pp. 2180-6
-
-
Rosendaal, F.R.1
Nieuwenhuis, H.K.2
van den Berg, H.M.3
Heijboer, H.4
Mauser-Bunschoten, E.P.5
van der Meer, J.6
Smit, C.7
Strengers, P.F.8
Briët, E.9
-
2
-
-
0027392864
-
A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
-
Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
-
(1993)
Thromb Haemost
, vol.69
, pp. 115-8
-
-
Peerlinck, K.1
Arnout, J.2
Gilles, J.G.3
Saint-Remy, J.M.4
Vermylen, J.5
-
3
-
-
0031048881
-
Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
-
Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
-
(1997)
Thromb Haemost
, vol.77
, pp. 80-6
-
-
Peerlinck, K.1
Arnout, J.2
Di Giambattista, M.3
Gilles, J.G.4
Laub, R.5
Jacquemin, M.6
Saint-Remy, J.M.7
Vermylen, J.8
-
4
-
-
67649855138
-
Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII
-
Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O'Brien A, Hayward B, Udata C, Roth DA, Arkin S. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 2009; 15: 869-80.
-
(2009)
Haemophilia
, vol.15
, pp. 869-80
-
-
Recht, M.1
Nemes, L.2
Matysiak, M.3
Manco-Johnson, M.4
Lusher, J.5
Smith, M.6
Mannucci, P.7
Hay, C.8
Abshire, T.9
O'Brien, A.10
Hayward, B.11
Udata, C.12
Roth, D.A.13
Arkin, S.14
-
5
-
-
37749022016
-
Report of Expert Meeting on Factor VIII Products and Inhibitor Development
-
European Medicines Agency. London: European Medicines Agency.
-
European Medicines Agency. Report of Expert Meeting on Factor VIII Products and Inhibitor Development. London: European Medicines Agency, 2007.
-
(2007)
-
-
-
6
-
-
79952044013
-
Office for Biologics Evaluation and Research and Office of Blood Research and Review and the International Association for Biologicals. The Factor VIII Inhibitor Workshop
-
US Food and Drug Administration (FDA). Bethesda, MD: US Food and Drug Administration (FDA).
-
US Food and Drug Administration (FDA). Office for Biologics Evaluation and Research and Office of Blood Research and Review and the International Association for Biologicals. The Factor VIII Inhibitor Workshop. Bethesda, MD: US Food and Drug Administration (FDA), 2003.
-
(2003)
-
-
-
7
-
-
0038383605
-
The epidemiology of inhibitors in haemophilia A: a systematic review
-
Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
-
(2003)
Haemophilia
, vol.9
, pp. 418-35
-
-
Wight, J.1
Paisley, S.2
-
8
-
-
0032973849
-
Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
-
White GC, DiMichele D, Mertens K, Negrier C, Peake IR, Prowse C, Schwaab R, Yoshioka A, Ingerslev J. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
-
(1999)
Thromb Haemost
, vol.81
, pp. 462
-
-
White, G.C.1
DiMichele, D.2
Mertens, K.3
Negrier, C.4
Peake, I.R.5
Prowse, C.6
Schwaab, R.7
Yoshioka, A.8
Ingerslev, J.9
-
10
-
-
0025622359
-
Evaluation of wet pasteurization of a factor VIII concentrate produced by controlled-pore silica adsorption
-
Hiemstra H, Nieuweboer CE, Idoe MA, Claassen JE, Vos AH, Tersmette M, Strengers PF, Over J, Mauser-Bunschoten EP, Heijboer H, Holdrinet ACJM. Evaluation of wet pasteurization of a factor VIII concentrate produced by controlled-pore silica adsorption. Folia Haematol Int Mag Klin Morphol Blutforsch 1990; 117: 557-63.
-
(1990)
Folia Haematol Int Mag Klin Morphol Blutforsch
, vol.117
, pp. 557-63
-
-
Hiemstra, H.1
Nieuweboer, C.E.2
Idoe, M.A.3
Claassen, J.E.4
Vos, A.H.5
Tersmette, M.6
Strengers, P.F.7
Over, J.8
Mauser-Bunschoten, E.P.9
Heijboer, H.10
Holdrinet, A.C.J.M.11
-
11
-
-
0042411064
-
Consensus perspectives on prophylactic therapy for haemophilia: summary statement
-
Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, Giangrande PL, Gringeri A, Ljung RC, Manco-Johnson MJ, Morfini M, Kilcoyne RF, Petrini P, Rodriguez-Merchan EC, Schramm W, Shapiro A, van den Berg HM, Hart C. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1-4.
-
(2003)
Haemophilia
, vol.9
, Issue.SUPPL. 1
, pp. 1-4
-
-
Berntorp, E.1
Astermark, J.2
Bjorkman, S.3
Blanchette, V.S.4
Fischer, K.5
Giangrande, P.L.6
Gringeri, A.7
Ljung, R.C.8
Manco-Johnson, M.J.9
Morfini, M.10
Kilcoyne, R.F.11
Petrini, P.12
Rodriguez-Merchan, E.C.13
Schramm, W.14
Shapiro, A.15
van den Berg, H.M.16
Hart, C.17
-
12
-
-
33751010515
-
Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development
-
Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006; 12: 102-6.
-
(2006)
Haemophilia
, vol.12
, pp. 102-6
-
-
Ettingshausen, C.E.1
Kreuz, W.2
-
13
-
-
77954506432
-
Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review
-
Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Mannucci PM, Nowak-Göttl U. Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review. J Thromb Haemost 2010; 8: 1256-65.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 1256-65
-
-
Iorio, A.1
Halimeh, S.2
Holzhauer, S.3
Goldenberg, N.4
Marchesini, E.5
Marcucci, M.6
Young, G.7
Mannucci, P.M.8
Nowak-Göttl, U.9
-
14
-
-
79952056432
-
-
EMEA Public Statement. Review of recombinant factor VIII (FVIII) products and inhibitor development, Available at Accessed 17 May 2010.
-
EMEA Public Statement. Review of recombinant factor VIII (FVIII) products and inhibitor development, 2005. Available at Accessed 17 May 2010.
-
(2005)
-
-
-
15
-
-
13244281593
-
Hemophilia replacement products, clinical trials: inhibitors and pharmacokinetics-can they be done?
-
Aledort LM. Hemophilia replacement products, clinical trials: inhibitors and pharmacokinetics-can they be done? J Thromb Haemost 2004; 2: 1855-6.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1855-6
-
-
Aledort, L.M.1
-
16
-
-
0347662157
-
Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy
-
Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
-
(1998)
Transfus Sci
, vol.19
, pp. 139-48
-
-
Giles, A.R.1
Rivard, G.E.2
Teitel, J.3
Walker, I.4
-
17
-
-
37149022850
-
Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers)
-
Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13: 65-8.
-
(2007)
Haemophilia
, vol.13
, pp. 65-8
-
-
Mannucci, P.M.1
Gringeri, A.2
Peyvandi, F.3
Santagostino, E.4
-
18
-
-
79952066105
-
-
Sippet Project. Survey of inhibitors in plasma-product exposed toddlers. Available at Accessed 15 October 2010.
-
Sippet Project. Survey of inhibitors in plasma-product exposed toddlers. Available at Accessed 15 October 2010.
-
-
-
-
19
-
-
44649131062
-
Performance of Bethesda assay and Nijmegen variant in external quality assessment (ECAT) of factor VIII inhibitor assays
-
Abstract O-T-093.
-
Verbruggen B, Meijer P. Performance of Bethesda assay and Nijmegen variant in external quality assessment (ECAT) of factor VIII inhibitor assays. J Thromb Haemost 2007;5(Suppl. 2): Abstract O-T-093.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.SUPPL. 2
-
-
Verbruggen, B.1
Meijer, P.2
-
20
-
-
79952065974
-
-
Centers for Disease Control and Prevention. Universal Data Collection (UDC) Inhibitor Pilot Project Fact Sheet for HTC Providers. Available at Accessed 15 October 2010.
-
Centers for Disease Control and Prevention. Universal Data Collection (UDC) Inhibitor Pilot Project Fact Sheet for HTC Providers. Available at Accessed 15 October 2010.
-
-
-
-
21
-
-
0037330233
-
The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development
-
Goodeve AC, Peake IR. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 2003; 29: 23-30.
-
(2003)
Semin Thromb Hemost
, vol.29
, pp. 23-30
-
-
Goodeve, A.C.1
Peake, I.R.2
-
22
-
-
64749096663
-
Inhibitors of factor VIII in black patients with hemophilia
-
Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
-
(2009)
N Engl J Med
, vol.360
, pp. 1618-27
-
-
Viel, K.R.1
Ameri, A.2
Abshire, T.C.3
Iyer, R.V.4
Watts, R.G.5
Lutcher, C.6
Channell, C.7
Cole, S.A.8
Fernstrom, K.M.9
Nakaya, S.10
Kasper, C.K.11
Thompson, A.R.12
Almasy, L.13
Howard, T.E.14
-
23
-
-
13844276825
-
A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates
-
Lee ML, Roth DA. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia 2005; 11: 5-12.
-
(2005)
Haemophilia
, vol.11
, pp. 5-12
-
-
Lee, M.L.1
Roth, D.A.2
-
24
-
-
47649131839
-
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients
-
rAHF-PFM Clinical Study Group.
-
Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM; rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
-
(2008)
J Thromb Haemost
, vol.6
, pp. 1319-26
-
-
Blanchette, V.S.1
Shapiro, A.D.2
Liesner, R.J.3
Hernández Navarro, F.4
Warrier, I.5
Schroth, P.C.6
Spotts, G.7
Ewenstein, B.M.8
-
25
-
-
2342574192
-
FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA, on 21 November 2003
-
Ingerslev J. FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA, on 21 November 2003. Haemophilia 2004; 10: 288-9.
-
(2004)
Haemophilia
, vol.10
, pp. 288-9
-
-
Ingerslev, J.1
|